Vericel CMO reports RSU vesting and tax share offsets
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported multiple equity compensation transactions tied to restricted stock units (RSUs).
Rhea-AI Filing Summary
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported multiple equity compensation transactions tied to restricted stock units (RSUs). On the transaction date, several RSU awards vested and were converted to common stock, and some RSUs were deferred into phantom stock under Vericel’s Deferred Compensation Plan. The company withheld 1,335 and 636 shares of common stock to satisfy tax obligations at fair market values of $38.09 and $38.25 per share. Following these transactions, Hopper directly owned 75,556 shares of Vericel common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
6,500 shares exercised/converted
Exercise
10 txns
Insider
Hopper Jonathan Mark
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 350 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 3,150 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 1,500 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 1,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 350 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,150 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,335 | $38.09 | $51K |
| Exercise | Common Stock | 1,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,500 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 636 | $38.25 | $24K |
Holdings After Transaction:
Restricted Stock Unit — 16,500 contracts (Direct);
Common Stock — 75,556 shares (Direct)
Footnotes (11)
- F1. The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
- F2. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
- F3. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F4. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
- F5. These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
- F6. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
- F7. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively.
- F8. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
- F9. No expiration date for this type of award.
- F10. The Fair Market Value of the vested derivative securities is $38.09 per share.
- F11. The Fair Market Value of the vested derivative securities is $38.25 per share.
FAQ
What insider transactions did Vericel (VCEL) report for Jonathan Mark Hopper?
Vericel’s Chief Medical Officer Jonathan Mark Hopper reported RSU vestings that converted into common stock and phantom stock. Some shares were withheld by the company to cover tax obligations, and his directly owned Vericel common stock increased to 75,556 shares after the transactions.
Were the Vericel (VCEL) insider transactions open-market buys or sales?
The transactions involved RSU vesting and derivative exercises, not open-market trades. Shares were acquired through equity awards, while certain shares were withheld by Vericel solely to satisfy tax withholding requirements associated with the vesting of those restricted stock units.
What are phantom stock units in the Vericel (VCEL) Deferred Compensation Plan?
Phantom stock units are deferred units payable only in Vericel common shares at a future distribution date. Certain vested RSUs were converted into phantom stock under Vericel’s Deferred Compensation Plan instead of immediate share delivery, aligning compensation with future benefit distribution elections.
What does each Vericel (VCEL) restricted stock unit represent for Jonathan Hopper?
Each Vericel restricted stock unit represents a contingent right to receive one share of Vericel common stock. As RSUs vest over scheduled future dates, they either convert into common shares or, if elected, into phantom stock units under the company’s Deferred Compensation Plan.
When will remaining Vericel (VCEL) RSUs for Jonathan Hopper vest?
Unvested RSUs granted to Jonathan Hopper on February 20, 2025 are scheduled to vest on February 20, 2027, February 20, 2028, and February 20, 2029. Additional RSUs granted on February 22, 2024 will vest on February 22, 2027 and February 22, 2028, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
